Research on type 2 diabetes and its management. Covers nerve pain, early onset, BMI trajectories, and treatment side effects.
A study found that CT scans can identify individuals at high risk of type 2 diabetes through automated analysis of various body components. The index of visceral fat showed the highest predictive performance for diabetes.
A large Danish study published in Diabetologia found no association between gestational diabetes and an increased risk of breast cancer. The study included over 708,000 women and followed them for a median of 11.9 years to examine the link between the two conditions.
A recent study found that type 2 diabetes significantly increases the risk of fractures in older women. The increased risk is thought to be primarily caused by impaired physical function rather than skeletal characteristics.
A recent paper surveys advances in diabetes pathogenesis and treatment, highlighting the role of genes, environmental factors, and social determinants. The study suggests that understanding these dynamics is key to developing targeted interventions to reduce diabetes risk and manage its complications.
Experts advocate for incorporating normalization of blood sugar regulation into diabetes prevention strategies. Studies show that weight loss-induced prediabetes remission can significantly reduce the risk of developing type 2 diabetes, especially when combined with lifestyle changes.
A nationwide study found a significant increase in GLP-1RA prescriptions for weight loss management, with a notable uptick since 2020. The researchers hope their findings will inform healthcare policies to ensure equitable access to these essential treatments.
A recent study found that long-term use of sulfonylureas increases the risk of impaired awareness of hypoglycemia in patients with type 2 diabetes. The longer the patient uses sulfonylureas, the higher the risk. Researchers suggest using newer classes of medications to reduce this risk.
A large cohort of primarily low-income, Black and white adults found persistently unhealthy sleep to be significantly associated with Type 2 diabetes. The study suggests that maintaining regular sleep schedules over time may reduce the risk of adverse cardiometabolic conditions.
A recent UNIGE study highlights the risks of high-protein diets, also known as Paleolithic diets, which can lead to severe neurological disorders. Excess protein increases ammonium production, overwhelming the liver and potentially causing coma in severe cases.
A study found that irregular sleep durations were associated with a higher risk of developing type 2 diabetes, even after adjusting for various risk factors. Participants with more inconsistent sleep patterns had a 34% increased risk compared to those with regular sleep patterns.
A study published in Science Advances reveals a special group of 'first responder' cells in the pancreas that trigger blood sugar response. These cells respond to glucose quicker than others, initiating the response and regulating the activity of other beta cells.
A study reveals that the gene SH2B1 controls feeding and energy expenditure, with mutations associated with obesity and metabolic diseases. Enhancing SH2B activity may offer a promising treatment for obesity and related conditions with fewer side effects.
A study found that both short and long sleep durations are associated with a higher risk of microvascular disease in individuals recently diagnosed with type 2 diabetes. Short sleep duration, especially among older adults, was linked to a significantly increased risk of blood vessel damage.
Researchers found that mice lacking certain signal molecules produced during exercise had reduced oxygen consumption and fat burning, leading to increased susceptibility to weight gain. In humans, those producing more of these alternative versions consumed less oxygen and had lower body fat.
A systematic review published in Nutrients highlights the positive health outcomes associated with pulse consumption. The study found that eating more pulses reduces the risk of type 2 diabetes and heart disease.
Researchers analyzed over 1.5 million patient records to find that metformin and SGLT-2 inhibitors lowered dementia and Alzheimer's disease risks compared to other antidiabetic drugs. The study suggests individualized treatment approaches considering patient-specific factors for optimal diabetes management.
A recent study published in Nature Medicine confirms the health benefits of a diet high in unsaturated plant fats, such as the Mediterranean diet. The research used lipidomics to measure diet-related fat changes in the blood and link them to disease risk.
Researchers from Mount Sinai and City of Hope demonstrate a combination treatment that increases human insulin-producing beta cells by 700% in mice with diabetes. This breakthrough could lead to new treatments for the hundreds of millions of people with diabetes worldwide.
Researchers at City of Hope and Mount Sinai have demonstrated a combination treatment that increases human insulin-producing beta cells by 700% in mice with type 1 and type 2 diabetes. The study, published in Science Translational Medicine, provides a potential new approach to treating the disease.
A cohort study found increased patient coinsurance in Medicare Part D's coverage gap and catastrophic coverage phases at age 65, associated with higher spending on T2D medications. This may lead to reduced diabetes medication utilization, increasing the risk of nonadherence and complications.
A new study has found that women with a family history of endocrine diseases, including type 2 diabetes and polycystic ovary syndrome, are at a higher risk of experiencing pregnancy loss. The study, which examined over 366,000 women in Denmark, found a significant association between endocrine disease and pregnancy loss.
Researchers found that combining sodium glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists reduces the risk of major adverse cardiovascular events and chronic kidney disease progression by 11% and 33%, respectively. The study suggests using this combination to further improve outcomes in patients with typ...
Researchers found GLP-1 receptor agonists lower risks of certain obesity-associated cancers in patients with type 2 diabetes, suggesting potential benefits for cancer prevention in high-risk populations. The study provides preliminary evidence supporting further preclinical and clinical studies to prevent specific obesity-linked cancers.
A recent study found that for every same increase of BMI, fat mass and type 2 diabetes risk are increased in taller people. The authors hypothesize that the cardiometabolic risk of a higher BMI may be underestimated in taller grown populations worldwide.
The study reveals a functional hierarchy of beta cells, with a small group acting as 'first responders' to initiate the glucose response. These cells produce and supply Vitamin B6 to regulate the activity of other beta cells, offering new insights into diabetes pathology and potential treatments.
A new study found that patients prescribed semaglutide for diabetes or weight loss have a higher risk of developing NAION, a potentially blinding eye condition. The study revealed a significant risk increase in diabetic and overweight/obesity patients taking semaglutide.
Researchers found that individual responses to proteins and fats can drive insulin production, challenging the long-held belief that fats have negligible effects on insulin release. This study has implications for tailored dietary guidance to manage blood sugar and insulin levels in individuals with diabetes or those at risk.
A new mouse study suggests that elenolic acid can lower blood sugar levels and promote weight loss in obese mice with diabetes. The compound was found to induce the release of metabolic hormones GLP-1 and PYY, leading to improved glucose regulation and insulin sensitivity.
Researchers found that people who achieved weight loss and prediabetes remission had a 76% lower risk of developing type 2 diabetes compared to those who only lost weight. This suggests that normalization of blood sugar levels should be included as a therapeutic goal in guidelines to improve diabetes prevention.
A large-scale study has found a consistent set of microbial species linked to type 2 diabetes across diverse populations. The researchers discovered that certain strains of bacteria have varied functions, including the ability to produce branched-chain amino acids, which may increase T2D risk.
A genetic variation common in people of African ancestry is associated with an increased risk of diabetic retinopathy and nephropathy. Testing for this variant could help clinicians diagnose and treat diabetes more effectively, reducing disparities in diabetes complications between individuals of European and African ancestries.
Research highlights need for prevention and treatment approaches for children with obesity born underweight, finding links between low birth weight and cardiometabolic disease risks. Visceral fat storage issues contribute to type 2 diabetes risk.
A Flinders University study found that exposure to brighter light at night is associated with a higher risk of developing type 2 diabetes. The research used data from approximately 85,000 people and tracked their light levels for nine years.
A new study from the University of Oklahoma found that measuring circulating microRNAs is likely as effective as measuring blood sugar levels in determining how young people with type 2 diabetes will fare. The study also found a 20% decrease in beta cell function during the first six months of treatment.
The ARMMS-T2D study found that bariatric surgery yields greater long-term improvements in quality-of-life compared to medical management, with sustained weight loss correlating with better health and reduced pain.
Researchers have developed a novel drug therapy for obstructive sleep apnea (OSA), which has shown significant improvements in reducing breathing interruptions and improving overall health. The treatment targets both respiratory and metabolic complications, providing a promising alternative to existing therapies.
A randomized clinical trial found that an intermittent fasting plan consisting of two nonconsecutive fasting days and five days of meal replacement diet improved glycemic outcomes and weight loss in the short term compared to metformin or empagliflozin. The study suggests a promising initial intervention for type 2 diabetes management.
A shift in testing for and managing Gestational Diabetes Mellitus (GDM) to much earlier in pregnancy may prevent health complications for both the mother and baby. GDM, a type of diabetes found during pregnancy, affects one in seven pregnancies worldwide.
A new study from the University of Eastern Finland finds that a healthy diet is associated with lower blood glucose levels and a reduced risk of prediabetes and type 2 diabetes. The association holds true for individuals with both low and high genetic risk, suggesting a universal benefit of healthy eating.
A study of almost 400,000 live births found that paternal use of metformin monotherapy was not significantly associated with major congenital malformations. However, researchers noted that fathers prescribed metformin had higher rates of cardiovascular and metabolic conditions, which could affect reproductive health.
A potential new strategy for reducing diabetes risk associated with antipsychotic medications involves co-administering drugs that block dopamine receptors in the brain alongside those that stop these same receptors in the pancreas. This approach may limit metabolic side effects and improve glucose metabolism.
A new study found that adolescents with higher rates of prediabetes often experience adverse social determinants of health, such as food insecurity and low household income. Screening for these non-medical factors may help identify youth at risk of progressing to type 2 diabetes.
A laboratory study found that passive heat exposure stresses the heart, increasing myocardial blood flow in all participants, regardless of age or health status. Adults with a history of CAD are at particular risk and may benefit from minimizing cardiac strain during extreme heat by staying cool.
A review article identifies new drug targets for treating type 2 diabetes, including growth differentiation factor (GDF15) and TGF-β pathways. Metformin's mechanism of action is also reevaluated, revealing a novel pathway of inhibiting mitochondrial complex IV.
Research shows that GLP-1 receptor agonist drugs are highly effective for weight management and Type 2 diabetes treatment, but they come with complex considerations such as dosages, side effects, and comparisons between specific drugs. Experts caution against overusing these drugs or viewing them as a universal cure-all for obesity.
A study found that telemedicine increased access to endocrinology care for adults with type 2 diabetes and cardiovascular disease, particularly those in rural areas and lower socioeconomic status. This enhancement of care access was primarily due to overcoming transportation barriers, mobility challenges, and long travel times.
Researchers found that GLP-1 receptor agonists and SGLT-2 inhibitors lower the risk of major cardiovascular events, such as heart attacks, and severe liver complications compared to other diabetes treatments. These medications also showed no significant increase in severe adverse events.
A comprehensive study found that living with obesity for 10 years or more significantly increases the risk of heart attacks and strokes. The research, published at ENDO 2024, analyzed data from over 109,000 participants and revealed a 25-60% increased risk in younger adults.
A recent study funded by tirzepatide maker Eli Lilly Inc. found that the medication resulted in significant weight loss regardless of the number of obesity-related complications patients had at the outset. The study combined data from four trials involving over 4,700 subjects with obesity or overweight conditions.
Researchers at Edith Cowan University have found a significant genetic connection between Type 2 Diabetes and certain gut disorders, which could lead to more effective therapies. The study uncovered shared biological origins with Type 2 Diabetes among gut conditions like stomach ulcers and irritable bowel syndrome.
A groundbreaking study reveals semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality in patients with type 2 diabetes and chronic kidney disease. Semaglutide also shows improved safety and efficacy profiles.
A new study reveals that a cancer drug can improve insulin sensitivity and lower blood glucose levels, but eliminating a specific gene related to fat metabolism worsens insulin resistance. The research highlights the interconnectedness of fat metabolism in organs and the need for simultaneous treatment of obesity and insulin sensitivity.
A national study found a significant increase in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) among adolescents and young adults in the US. Female adolescents showed a higher increase in GLP-1RA usage compared to males, highlighting the need for education on potential safety risks during pregnancy.
This study found that genetic variants rs16890979 and rs206833 are associated with T2DM control in the northern Jordanian population. The AA genotype at the rs206833 variant was linked to reduced T2DM control, while the CT genotype at the rs16890979 variant was also found to be statistically significant.
Researchers are exploring the connection between high-fat diets and Type 2 diabetes, with a focus on the REDD1 protein in heart cells. Insulin resistance in heart cells doubles the risk of heart failure and death, highlighting the need for new treatments for diabetic heart disease.
Researchers are studying the early brain development of babies born to mothers with diabetes to understand the link between prenatal exposure and later childhood obesity. They aim to identify key differences in brain structure and function that may contribute to the increased risk of obesity.
Researchers developed an algorithm to stratify people with type 2 diabetes using routine data, revealing metabolic diversity and insulin sensitivity variability. The study's findings have the potential to change the way we understand and treat type 2 diabetes.
Two studies based on the SELECT trial show semaglutide leads to sustained weight loss of 10% body weight and 7cm waist reduction after 4 years, regardless of starting weight or BMI. The medication also delivers cardiovascular benefits, with a lower risk of heart attack, stroke, or death.
Researchers found that Kallistatin expression increases after weight loss in individuals with overweight and obesity. Additionally, human Kallistatin improves hepatic insulin sensitivity in diet-induced obese mice. The study suggests that Kallistatin may be an interesting therapeutic target for people with obesity and type 2 diabetes.
A Swedish study of people living with obesity found that poor muscle health is associated with a higher risk of an early death. Adverse muscle composition was up to three times more likely to lead to death during the course of the study than those with healthy muscles.